Viewing nowCombinationCandelova Tablet 5/8 mg
Rosuvastatin Calcium 5.2mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.

MFDS item code 202008711 · Approved 2020.12.11
Treatment of hypertension, heart failure, and dyslipidemia; suppression of atherosclerosis progression and cardiovascular risk
This medication is developed for patients who need to take Candesartan Cilexetil and Rosuvastatin together. Candesartan Cilexetil is used in patients with essential hypertension or heart failure with left ventricular systolic dysfunction when additional treatment beyond ACE inhibitors is needed or if they are intolerant to such treatment. Rosuvastatin is used as an adjunct in the treatment of hyperlipidemia, especially when not controlled by diet and exercise, and helps to slow the progression of atherosclerosis and reduce the risk of cardiovascular disease. Furthermore, it helps reduce the risk of stroke, myocardial infarction, and vascular reintervention in patients at high risk for cardiovascular diseases. Therefore, this medication is used to manage cholesterol levels in the blood while controlling blood pressure, improving cardiovascular health.
This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: An oral dose of 8 ∼ 16 mg of candesartan cilexetil once daily is recommended as the initial and maintenance dose. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect occurs within 4 weeks of starting treatment. 2) Older adults: No initial dose adjustment is necessary. 3) Patients with intravascular volume depletion: For patients at increased risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient’s response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient’s response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. Double the dose at intervals of 2 weeks or more, taking the patient’s tolerability into account, up to a maximum of 32 mg once daily. 2) Older adults, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No initial dose adjustment is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more, based on LDL cholesterol levels, treatment goals, and the patient’s response; the dose may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.
Adolescents and children aged 18 years or younger: Safety and efficacy have not been established. Adolescents and children aged 18 years or younger: Safety and efficacy have not been established.
This medication can cause serious harm to the fetus and newborn during pregnancy, so it must be discontinued immediately once pregnancy is confirmed. Patients with an allergy to this medication or its components, liver disease, severe hepatic impairment, severe renal failure, hereditary angioedema, pregnant or breastfeeding women, and those with myopathy should not take this medication. Elderly patients and those with hyperkalemia, liver dysfunction, cardiac diseases, renal dysfunction should use this medication with greater caution, and renal function and potassium levels should be routinely monitored through blood tests. This medication can cause myalgia or muscle weakness, and in rare cases, severe muscle damage (rhabdomyolysis), so if unexplained muscle pain or weakness occurs during treatment, a physician should be consulted immediately. Regular liver function tests are crucial for assessing the impact on liver function before and during treatment. Care should be taken when taking this medication with other drugs, particularly potassium-sparing diuretics, certain antibiotics, antifungals, immunosuppressants, and fibrate agents, as interactions may occur. Women who might become pregnant should use adequate contraception, and this medication should not be taken during pregnancy or lactation. In cases of overdose, symptoms such as hypotension, dizziness, and tachycardia may occur, so immediate medical attention is required. There is no specific antidote, and treatment will be symptom-based. During treatment, temporary dizziness or fatigue due to blood pressure-lowering effects may occur, so caution should be exercised when driving or operating machinery. Keep this medication out of reach of children, and it is safer not to transfer the medication from its original container to another.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture ingress, and it should be kept at room temperature between 1°C and 30°C. Proper storage will help maintain the effectiveness of the medication.
Pink round film-coated tablet
30 tablets (10 tablets per PTP X 3) - 30 tablets/PTP [30 tablets (10 tablets/PTP X 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationRosuvastatin Calcium 5.2mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
AlboGen Korea Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Candesartan Cilexetil 32mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 16mg
Tablet · Prescription medication · Combination
Alvogen Korea Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Alvogen Korea Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 16mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.